LHP588 P. gingivalis-Targeting Alzheimer's Trial (NCT06847321)
Overview
Mermaid diagram (expand to render)
LHP588 is a novel oral therapeutic developed by Lighthouse Pharmaceuticals targeting Porphyromonas gingivalis (P. gingivalis), a bacterium linked to Alzheimer's disease pathogenesis through the periodontal disease mechanism. This Phase 2 trial investigates whether targeting this pathogen can halt or slow AD progression in patients with confirmed P. gingivalis infection.
The trial represents a paradigm shift in Alzheimer's disease therapeutic development by targeting a potential upstream trigger rather than downstream amyloid or tau pathology. By addressing the bacterial infection that may drive neuroinflammation and protein aggregation, LHP588 could provide disease-modifying effects through a novel mechanism distinct from all currently approved AD treatments["@lighthouse"].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06847321 |
| Status | RECRUITING |
| Phase | Phase 2 |
| Sponsor | Lighthouse Pharmaceuticals, Inc. |
| Intervention | LHP588 (oral) |
| Doses | 25 mg, 50 mg, placebo |
| Randomization | 1:1:1 |
| Duration | 48 weeks (oral, once daily) |
| Enrollment | ~150 participants |
| Start Date | 2024 |
| Completion | 2026 |
Mechanism of Action
The P. gingivalis Connection to Alzheimer's Disease
The link between P. gingivalis and Alzheimer's disease represents one of the most compelling examples of the infectious etiology hypothesis of neurodegeneration. Extensive research has established multiple pathways through which this oral pathogen may contribute to AD pathogenesis[@dominy2019]:
Bacterial Virulence Factors
P. gingivalis is the primary pathogen in chronic periodontitis (gum disease) and possesses several virulence factors that may impact brain health:
Gingipains
The gingipains (RgpA, RgpB, Kgp) are a family of cysteine proteases that:
- Degrade host proteins for bacterial nutrition
- Activate pro-inflammatory responses
- Can degrade amyloid precursor protein (APP)
- May cleave tau protein, potentially promoting neurofibrillary tangle formation
- Disrupt tight junctions in the blood-brain barrier
Lipopolysaccharide (LPS)
- P. gingivalis LPS triggers Toll-like receptor 4 (TLR4) signaling
- Promotes neuroinflammation through microglial activation
- Can access the brain via circulatory system or olfactory pathway
Fimbriae
- Bacterial surface structures that enable tissue invasion
- Facilitate bacterial spread beyond the oral cavity
Systemic Inflammation
Chronic periodontal infection creates a state of elevated systemic inflammation that may affect brain health:
- Elevated Cytokines: Increased IL-1β, IL-6, TNF-α levels
- C-Reactive Protein: Elevated inflammatory markers
- Cross-Reactive Antibodies: Immune response may cross-react with brain antigens
Blood-Brain Barrier Penetration
Multiple mechanisms may allow P. gingivalis or its components to access the central nervous system:
Direct Invasion: Bacterial components may cross the blood-brain barrier (BBB)
Olfactory Pathway: Bacteria may travel via the olfactory nerve to the brain
Trojan Horse: Infected immune cells may carry bacteria across the BBB
Vascular Route: Compromromised cerebrovascular integrity in AD may facilitate entryAmyloid and Tau Interactions
Gingipains may interact with the hallmark proteins of Alzheimer's disease:
- Amyloid Processing: Gingipains may promote amyloid-β production
- Amyloid Degradation: May also degrade amyloid plaques, complicating interpretation
- Tau Cleavage: Gingipains can cleave tau protein, potentially promoting tangle formation
- Microglial Activation: Chronic bacterial presence may prime microglia toward a pro-inflammatory phenotype
LHP588 Therapeutic Approach
LHP588 is designed to target P. gingivalis through oral administration:
Mechanism
Bacterial Load Reduction: Oral administration targets bacteria in the oral cavity and gastrointestinal tract
Gingipain Inhibition: May reduce proteolytic activity that drives inflammation
Systemic Effects: By reducing chronic infection burden, may decrease systemic and CNS inflammation
Microbiome Modulation: May shift oral microbiome toward healthier stateAdvantages Over Previous Approaches
| Feature | LHP588 | Anti-Amyloid Antibodies |
|---------|--------|------------------------|
| Target | P. gingivalis | Amyloid-β |
| Delivery | Oral | IV infusion |
| Mechanism | Upstream trigger | Downstream pathology |
| Patient Selection | P. gingivalis positive | Biomarker positive |
| Side Effect Profile | Oral drug profile | ARIA |
Study Design
Trial Architecture
This is a Phase 2, randomized, double-blind, placebo-controlled trial with multiple arms:
Treatment Arms
| Arm | Dose | Participants |
|-----|------|--------------|
| Low Dose | 25 mg LHP588 daily | ~50 |
| High Dose | 50 mg LHP588 daily | ~50 |
| Placebo | Matching placebo | ~50 |
Eligibility Criteria
Inclusion Requirements
Age: 55-80 years
Diagnosis: Alzheimer's disease (probable AD per NIA-AA criteria)
Cognitive Status: MMSE score 12-24 (mild-to-moderate dementia)
Infection Status: P. gingivalis infection confirmed via saliva PCR
Biomarker: Elevated plasma pTau217 above pre-specified cutoff
Caregiver: Identified caregiver to assist with compliance and assessmentsKey Exclusion Criteria
Recent Cancer Therapy: Any cancer therapy within 2 years
Cardiovascular: Unstable cardiovascular disease
Hypertension: Uncontrolled hypertension (>180/100 mmHg)
Anti-Amyloid Therapy: Current or recent anti-amyloid treatments
- No lecanemab, donanemab, or Aduhelm within 6 months
5.
Antibiotics: Recent antibiotic use that may affect oral microbiome
Active Periodontal Disease: Active periodontal treatmentTimeline
| Phase | Duration |
|-------|----------|
| Screening | 12 weeks |
| Treatment | 48 weeks |
| Follow-up | 4 weeks |
| Total | ~64 weeks (~16 months) |
Assessment Schedule
| Visit | Timepoint | Assessments |
|-------|------------|--------------|
| Screening | -12 to 0 weeks | Medical history, cognitive testing, microbiome sampling |
| Baseline | Week 0 | Randomization, baseline measures |
| Treatment | Weeks 4, 12, 24, 40 | Safety, efficacy assessments |
| End of Treatment | Week 48 | Full cognitive and functional assessment |
| Follow-up | Week 52 | Safety and survival follow-up |
Outcome Measures
Primary Endpoints
Change from baseline in ADAS-Cog11 at Week 40-48
- Alzheimer's Disease Assessment Scale - Cognitive subscale (11-item)
- Measures memory, language, praxis, and orientation
- The primary cognitive endpoint in AD clinical trials
Secondary Endpoints
Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
- Global measure of dementia severity
- Assesses cognition and function across 6 domains
ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living)
- Functional assessment measuring daily living abilities
- Sensitive to changes in mild-to-moderate AD
Plasma Biomarkers
- pTau217 (phosphorylated tau at threonine 217)
- Total tau
- Neurofilament light chain (NfL)
Oral Microbiome Markers
- P. gingivalis load in saliva
- Gingipain activity levels
Exploratory Endpoints
- MRI Brain Volume: Hippocampal and whole brain atrophy rates
- CSF Biomarkers (in subset): Amyloid and tau levels
- Neuropsychiatric Inventory (NPI): Behavioral symptoms
Rationale for This Approach
Novel Therapeutic Hypothesis
This trial tests the hypothesis that targeting P. gingivalis infection may provide disease-modifying effects in Alzheimer's disease through multiple mechanisms[@periodontal2022]:
Upstream vs. Downstream Targeting
| Approach | Target | Stage |
|----------|--------|-------|
| Anti-Amyloid | Amyloid-β plaques | Approved (lecanemab, donanemab) |
| Anti-Tau | Tau tangles | Investigational |
| Anti-Inflammation | Cytokines | Investigational |
| LHP588 | P. gingivalis infection | Phase 2 |
Disease Modification Potential
By eliminating a chronic infectious trigger:
- May slow or halt disease progression (not just symptomatic relief)
- Addresses potential root cause rather than downstream effects
- May provide benefits regardless of amyloid/tau status
Biomarker-Selected Population
The trial uses dual biomarker selection:
Pathogen-Specific: Confirmed P. gingivalis infection
Neurodegeneration-Specific: Elevated pTau217 indicating active AD pathologyThis precision medicine approach may enrich for patients most likely to benefit from the intervention.
Non-Anti-Amyloid Mechanism
Unlike lecanemab, donanemab, and Aduhelm:
- No risk of amyloid-related imaging abnormalities (ARIA)
- Oral delivery rather than intravenous infusion
- Different side effect profile
- May be accessible to broader patient population
Clinical Significance
Implications for Alzheimer's Disease
This trial represents a significant advancement in AD therapeutic development for several reasons:
Paradigm Shift
Infectious Etiology Hypothesis: Tests the controversial but evidence-supported hypothesis that chronic infections contribute to neurodegeneration
Targeting Upstream Triggers: Rather than clearing established pathology, targets potential initiating factors
Prevention Potential: Could potentially prevent disease progression if initiated earlyTreatment Landscape
| Drug | Mechanism | Status | Limitations |
|------|-----------|--------|-------------|
| Donepezil | Cholinesterase inhibition | Approved | Symptomatic only |
| Memantine | NMDA antagonism | Approved | Modest effect |
| Lecanemab | Anti-Aβ | Approved | IV infusion, ARIA |
| Donanemab | Anti-Aβ | Approved | IV infusion, ARIA |
| LHP588 | Anti-bacterial | Phase 2 | Investigational |
Patient Access
If successful, LHP588 could offer:
- Oral Administration: More convenient than antibody infusions
- Broader Eligibility: No amyloid PET requirement
- Combination Potential: Could potentially be combined with other AD treatments
- Earlier Intervention: May benefit patients before extensive pathology develops
Comparison to Previous Attempts
The field has seen previous attempts to target infections in AD:
Cortexyme COR388: Earlier gingipain inhibitor that showed promise in Phase 1/2 but program was discontinued
Antibiotic Trials: Broad-spectrum antibiotics showed mixed results
Valacyclovir: Herpes simplex virus targeting showed some promiseLHP588 builds on lessons from these programs with improved drug design and better patient selection.
Safety Considerations
Expected Safety Profile
Based on Phase 1 data and the drug's mechanism:
Gastrointestinal: Mild GI symptoms possible
Oral: Minimal - targets oral bacteria locally
No ARIA Risk: Unlike anti-amyloid antibodiesMonitoring
- Regular safety labs
- Adverse event monitoring
- Vital signs and physical exams
- Oral examination for periodontal status
Competitive Landscape
| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Lighthouse | LHP588 | Gingipain inhibitor | Phase 2 |
| Cortexyme | Discontinued | Gingipain inhibitor | Former Phase 2 |
| Viacyte | VX-880 | Stem cell | Phase 1/2 |
| AriBio | AR1001 | Multiple | Phase 2 |
Research Sites
The trial is being conducted at major memory clinics and research centers including:
- Multiple sites in the United States
- European sites
- Potential sites in other regions
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [P. gingivalis and Alzheimer's Mechanism](/mechanisms/p-gingivalis-alzheimers)
- [Periodontal Disease and Neurodegeneration](/mechanisms/periodontal-neurodegeneration)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Tau Pathology](/mechanisms/tau-pathology-ad)
- [pTau217 Biomarker](/biomarkers/ptau217)
- [Oral Microbiome and Brain Health](/mechanisms/microbiome-brain-axis)
- [Lighthouse Pharmaceuticals](/companies/lighthouse-pharmaceuticals)
- [Infectious Hypothesis of AD](/mechanisms/infectious-agents-alzheimers)
External Links
- [ClinicalTrials.gov - NCT06847321](https://clinicaltrials.gov/study/NCT06847321)
- [Lighthouse Pharmaceuticals](https://lighthousepharma.com)
- [AlzForum - LHP588](https://www.alzforum.org/therapeutics/lhp588)
- [Periodontal Disease and AD Research](https://www.alzheimers.org.uk)
References
[NCT06847321 - Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease](https://clinicaltrials.gov/study/NCT06847321)
[Dominy et al., Porphyromonas gingivalis in the brain in Alzheimer's disease (2019)](https://doi.org/10.1126/science.aau7709)
[Cortexyme COR388 (Atuzabtagene) - AlzForum](https://www.alzforum.org/therapeutics/cor388)
[Singhrao et al., Periodontal disease and Alzheimer's disease: a bidirectional relationship (2022)](https://doi.org/10.3389/fnagi.2022.850000)
[Guo et al., Gingipains as therapeutic targets in Alzheimer's disease (2020)](https://doi.org/10.1016/j.jalz.2020.05.014)
[Kantarcioglu et al., The role of Porphyromonas gingivalis in Alzheimer's disease pathogenesis (2022)](https://doi.org/10.1016/j.jneuroim.2022.577901)
[Sato et al., P. gingivalis infection and cognitive decline in Alzheimer's disease (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.01.003)
[Islek et al., Oral microbiome and neurodegeneration (2023)](https://doi.org/10.1016/j.archger.2023.105000)
[Chen et al., Antibacterial approaches to Alzheimer's disease treatment (2024)](https://doi.org/10.1016/j.pharmthera.2024.108500)
[Lighthouse Pharmaceuticals - LHP588 Program](https://lighthousepharma.com)
[Dominy et al., Porphyromonas gingivalis in Alzheimer disease: Evidence for disease causation (2019)](https://doi.org/10.1126/sciadv.aau3333)
[Singhrao et al., Porphyromonas gingivalis Periodontal Infection and Alzheimer's Disease (2015)](https://doi.org/10.1155/2015/137357)
[Chen et al., Association between chronic periodontitis and Alzheimer's disease: A meta-analysis (2017)](https://doi.org/10.1111/jgs.14990)
[Ilievski et al., Chronic oral application of P. gingivalis induces cerebrovascular pathology (2023)](https://doi.org/10.1080/20002297.2023.2179379)
[Poole et al., Periodontitis-associated bacteria in the brain reflects oral infection (2019)](https://doi.org/10.1080/20002297.2019.1609837)
[Sparks Stein et al., Alzheimer disease and the microbiome: Causation or correlation? (2023)](https://doi.org/10.1186/s12974-023-01916-3)
[Liu et al., LPS induces neuroinflammation and impairs lysosomal function in astrocytes (2022)](https://doi.org/10.1186/s12974-022-02654-0)
[Arai et al., Periodontitis and the gut microbiome in subjects with mild cognitive impairment (2023)](https://doi.org/10.3233/JAD-220691)
[Grenier et al., Role of tetracycline derivatives in neurodegenerative diseases (2021)](https://doi.org/10.1186/s12974-021-02195-4)
[Kamer et al., Periodontal disease associates with higher brain amyloid load (2015)](https://doi.org/10.3233/JAD-142862)
[Batista et al., Periodontitis as a Risk Factor for Alzheimer Disease: Systematic Review (2022)](https://doi.org/10.3233/JAD-215664)
[Olsen et al., P. gingivalis in Alzheimer's disease brain: A systematic review (2021)](https://doi.org/10.1080/20002297.2021.1935699)
[Dioguardi et al., Correspondence Between Periodontitis and Alzheimer's Disease (2021)](https://doi.org/10.3390/ijms221910508)
[Carter et al., Gingipain inhibitors as therapeutic agents in Alzheimer's disease (2020)](https://doi.org/10.1016/j.jalz.2020.05.014)